entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 18:20:07 - browse：95888

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： How a small hospital in rural Puerto Rico survived Hurricane Maria

WSS

PBM executives asked to testify by House panel

Brain technologies pose threats that are all too real, experts warn

HHS's proposed rule does nothing to address the climate crisis

DeSantis can now import cheaper drugs. But will Biden get credit?

BIO to announce reorganization, senior leaders expected to depart

Idaho abortion case may prompt more restrictions in other states

hotspot

entertainment

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

How one medical school became remarkably diverse

Can gargling with Listerine treat gonorrhea of the mouth?

Psychedelics group wrestles with new pharma identity

Most antidepressants don't work on kids, teens, study finds

Duchenne breakthrough therapy leaves behind pioneering families

Chemotherapy before breast cancer surgery might fuel metastasis

Novavax promises a turnaround & Lilly roils the obesity market

Empower primary care with adequate payments and technology

Wikipedia

AI for drug discovery: Experts on separating hype from reality

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Idaho abortion case may prompt more restrictions in other states

New menopause drug shows promise in relief for hot flashes

Caregivers of transplant patients call for more support, training

AltruBio raises $225 million to develop ulcerative colitis drug

entertainment

hotspot

focus

leisure time